← 홈

CGT · 혈액암 (AML/ALL)

383개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 383개
CGTBiologicstaleMEI HENGPhase 1

CT0991 CAR-T cells infusicn (CT0991 CAR-T cells infusicn)

Relapsed/Refractory Acute Myeloid Leukemia(AML) · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleChi Kong LiPhase 2

CUCART19 (CUCART19)

Lymphoma, Nonhodgkin; Leukemia, Lymphocytic · Lymphoma, Nonhodgkin

#LymphomaNonhodgkin#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleJohn ListerPhase 2

Chimeric Antigen Receptor (CAR, Chimeric Antigen Receptor, Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous))

B-Cell Lymphoma; B Acute Lymphoblastic Leukemia · B-Cell Lymphoma

#B-CellLymphoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleSouthwest Hospital, ChinaPhase 2

Chimeric Antigen Receptor Modified T cells Targeting CD19 (Chimeric Antigen Receptor Modified T cells Targeting CD19)

Leukemia; Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleNelson HamerschlakPhase 1

Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0 (Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0)

Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleWashington University School of…Phase 2

Cytokine-induced memory-like NK cells (Cytokine-induced memory-like NK cells)

Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 DISCONTINUED
CGTBiologicstaleShanghai General Hospital, Shan…Phase 1

Dasatinib plus anti-CD19/CD22 CAR-T cells (Dasatinib plus anti-CD19/CD22 CAR-T cells)

Ph Positive ALL; CAR-T Cell · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleMasonic Cancer Center, Universi…Phase 2

Donor TCR α/β-depleted Graft/ATG (Donor TCR α/β-depleted Graft/ATG)

Acute Myeloid Leukemia; Myelodysplastic Syndrome · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleBeijing GoBroad HospitalPhase 1

Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy (Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy)

B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleGerman Cancer Research CenterPhase 1

Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion)

Relapsed/Refractory Acute Myeloid Leukemia (AML) · CD33

#CD33#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleBaylor College of MedicinePhase 1

Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells (Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells)

Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleMedical College of WisconsinPhase 1

Dose expansion: The maximum tolerated dose of CAR20.19.22 cells (Dose expansion: The maximum tolerated dose of CAR20.19.22 cells)

B-cell Non Hodgkin Lymphoma; B-cell Chronic Lymphocytic Leukemia · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleBeijing Boren HospitalPhase 1

Dual CD33/CLL1 CAR T (Dual CD33/CLL1 CAR T)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleBeijing BiotechPhase 2

EB-DT-CAR-NK (Dual-target CAR-NK cells, Dual-target CAR-NK cells (EB-DT-CAR-NK))

Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer · HER2

#HER2#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleUniversity of Kansas Medical Ce…Phase 1

DuoCAR20.19.22-D95 (DuoCAR20.19.22-D95)

B-Cell Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia · B-Cell Non-Hodgkin Lymphoma

#B-CellNon-HodgkinLymphoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing BiotechPhase 2

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing BiotechPhase 2

MSLN + MUC1 (EB-DNK101 dual-targeting CAR-NK cells, EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · Pancreatic Ductal Adenocarcinoma (PDAC)

#PancreaticDuctalAdenocarcinomaPD#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing BiotechPhase 2

CLDN18.2 + MUC1 (EB-DNK102 dual-targeting CAR-NK cells, EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · CLDN18.2

#CLDN182#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleJuno Therapeutics, Inc., a Bris…Phase 1

EGFRt/19-28z/4-1BBL CAR T cells (EGFRt/19-28z/4-1BBL CAR T cells)

Chronic Lymphocytic Leukemia (CLL); Relapsed · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleRoswell Park Cancer InstitutePhase 1

EGFRt/19-28z/IL-12 CAR T-lymphocytes (EGFRt/19-28z/IL-12 CAR T-lymphocytes)

Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 DISCONTINUED

14 / 20 페이지

← 이전다음 →